Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update
XERMELO® (telotristat ethyl) Quarterly U.S. Net Sales of $6.0 Million, Up 65% from Prior Year Quarter and 11% Quarter-Over-Quarter Filings for Regulatory Approval of Sotagliflozin in Type 1 Diabetes Accepted THE WOODLANDS, Texas, July 30, 2018 (GLOBE …